Typbar TCV

Typbar TCV is world’s first typhoid vaccine clinically proven to be administered to children from six months of age to adults, and confers long-term protection against typhoid fever. It has been evaluated in Human Challenge Studies at Oxford University.

The World Health Organisation (WHO) has given its pre-qualification to Typbar Typhoid Conjugate Vaccine (TVC) developed by Hyderabad based Bharat Biotech. The WHO pre-qualification enables procurement and supplies of this life-saving vaccine to UNICEF, Pan-American Health Organisation (PAHO) and GAVI (vaccine alliance) supported countries. This also paves the way for WHO member countries to introduce the Typbar TCV into their immunization programs.